Funding for this research was provided by:
Wilhelm och Else Stockmanns Stiftelse
Stiftelsen Dorothea Olivia, Karl Walter och Jarl Walter Perkléns Minne
Diabetes Wellness Suomi Säätiö
Medicinska Understödsföreningen Liv och Hälsa
Signe ja Ane Gyllenbergin Säätiö
Novo Nordisk Fonden
Helsinki University Central Hospital Research Funds and the Academy of Finland
Waldemar von Frenckell Foundation
Received: 16 March 2019
Accepted: 25 June 2019
First Online: 9 July 2019
Ethics approval and consent to participate
: The local ethics committee of each center approved the study protocol, and the study was carried out in accordance with the Declaration of Helsinki. Each participant signed a written informed consent.
: Not applicable.
: TT. has served on scientific advisory boards for Bayer, Boehringer Ingelheim, Lumosa Pharm, and Pfizer; T.T. has received speaker´s bureau from University of Donau (Austria). P.-H.G. has received research grants from Eli Lilly and Roche. He is an advisory board member for AbbVie, Astra Zeneca, Boehringer-Ingelheim, Cebix, Eli Lilly, Janssen, MSD, Medscape, Novartis, and Sanofi. He has also received speaker honorariums from Astra Zeneca, Boehringer-Ingelheim, Eli Lilly, Elo Water, Genzyme, MSD, Novartis, Novo Nordisk, and Sanofi. Other authors have no competing interests relevant to this paper.